Growth Hormone as Biomarker in Heart Failure

Alberto M. Marra, Emanuele Bobbio, Roberta D'Assante, Andrea Salzano, Michele Arcopinto, Eduardo Bossone, Antonio Cittadini

Research output: Contribution to journalReview article

Abstract

The impairment of growth hormone (GH)/insulin growth factor-1(IGF-1) plays a crucial role in chronic heart failure (CHF). Several studies have shown that patients affected by this condition display a more aggressive disease, with impaired functional capacity and poor outcomes. Interestingly, GH replacement therapy represents a possible future therapeutic option in CHF. In this review, the authors focus on the assessment of the main abnormalities in GH/IGF-1 axis in CHF, the underlying molecular background, and their impact on disease progression and outcomes.

Original languageEnglish
Pages (from-to)65-74
Number of pages10
JournalHeart Failure Clinics
Volume14
Issue number1
DOIs
Publication statusE-pub ahead of print - Nov 17 2017

Keywords

  • Anabolic deficiency
  • Biomarker
  • Chronic heart failure
  • Growth hormone
  • IGF-1
  • Outcomes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Growth Hormone as Biomarker in Heart Failure'. Together they form a unique fingerprint.

  • Cite this

    Marra, A. M., Bobbio, E., D'Assante, R., Salzano, A., Arcopinto, M., Bossone, E., & Cittadini, A. (2017). Growth Hormone as Biomarker in Heart Failure. Heart Failure Clinics, 14(1), 65-74. https://doi.org/10.1016/j.hfc.2017.08.008